Keep pulling the thread on Emma Walmsley.
GSK expects to receive regulatory approval for five new drugs and vaccines this year.
GSK expects to launch 14 major medicines and vaccines this decade, each with a sales potential of over £2 billion.
GSK has a new multiple myeloma drug, based on antibody-drug conjugate technology, with data showing it extends patient life expectancy by three years.
GSK is developing a potential functional cure for Hepatitis B using oligonucleotide technology, a disease that affects 250 million people worldwide.
GSK launched the world's first RSV vaccine last year.
GSK's oncology business more than doubled in revenue last year.
GSK used AI to analyze infectious disease patterns, which accelerated the clinical trial outcomes for its RSV vaccine by two years.
GSK's CEO predicts that within 10 years, AI will transform the company's R&D from a linear process to a "lab in a loop" model based on reverse translation from patient data.
GSK announced an additional $800 million investment in its US-based medicine and vaccine manufacturing capabilities last year.
GSK has added £7 billion to its long-term sales outlook over the past four years and now expects to grow sales by £17 billion this decade.
GSK has reduced its total headcount from 100,000 employees to approximately 70,000.
The Norwegian Sovereign Wealth Fund owns a 1.7% stake in GSK, valued at 1.3 billion US dollars.